Skip to main content
Premium Trial:

Request an Annual Quote

Lumera Lines up $25M in Equity Financing over Three Years

NEW YORK (GenomeWeb News) - Lumera said today it will have access to as much as $25 million in financing over the next three years through an equity financing agreement with investment bank Kingsbridge Capital Limited.

Lumera, which will choose the timing and amount of any of the committed equity financing facility purchases, plans to use the funds to support corporate and research and development activities.

The funds will be available to Lumera through tranches under which Kingsbridge will buy Lumera’s common stock at discounts between six percent and 12 percent, depending on the average market price of the stock during an eight-day pricing period.

Lumera also issued a warrant to Kingsbridge to buy up to 180,000 shares of common stock at $3.01 per share, which is a 125 percent premium over Lumera’s closing price over the five days before the agreement was signed.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.